Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Decrease in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 4,500 shares, a drop of 46.4% from the February 28th total of 8,400 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 7,100 shares, the short-interest ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, March 20th.

Xenetic Biosciences Price Performance

Xenetic Biosciences stock opened at $3.12 on Friday. The firm has a 50-day moving average of $3.89 and a 200-day moving average of $3.97. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20. The company has a market cap of $4.81 million, a price-to-earnings ratio of -1.17 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The firm had revenue of $0.65 million during the quarter, compared to the consensus estimate of $0.18 million. As a group, sell-side analysts expect that Xenetic Biosciences will post -1.01 earnings per share for the current year.

Institutional Trading of Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC grew its holdings in Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,550 shares of the company’s stock after purchasing an additional 9,700 shares during the quarter. Renaissance Technologies LLC owned about 1.66% of Xenetic Biosciences worth $102,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 15.12% of the stock is owned by hedge funds and other institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.